Attoplex Co., Ltd. is a molecular diagnostics company based in South Korea, specializing in the development of in vitro diagnostic technologies, molecular POCT platforms, real-time PCR assays, and genetic testing services.
Our core platform, GenHome, is a molecular point-of-care testing system designed to combine the accuracy of gene amplification technology with the convenience of rapid testing. Based on isothermal amplification and an all-in-one cartridge format, GenHome enables simple operation and rapid result confirmation, making it suitable for decentralized testing environments such as clinics, community healthcare settings, and field applications.
At WHX Osaka, Attoplex introduces its molecular diagnostic solutions for women’s health and sexual health, including GenHome-based STI POCT technology concepts for syphilis and HPV16/18 detection, as well as a real-time PCR-based vaginitis testing service planned for the Japanese clinic market.
Our vaginitis testing service, analyzes beneficial and harmful vaginal microorganisms using real-time PCR technology. The service provides clinically useful insights such as vaginal microbiome type classification, beneficial/harmful bacteria balance, quantitative analysis, and an easy-to-understand report designed to support patient consultation and follow-up care.
Attoplex aims to collaborate with Japanese clinics, healthcare service providers, diagnostic companies, and commercialization partners to bring practical, accurate, and accessible molecular diagnostic solutions to the Japanese healthcare market.